Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease

被引：12

作者：

Alongi, Filippo ^{[1
,5
]}

Arcangeli, Stefano ^{[2
]}

Triggiani, Luca ^{[3
]}

Mazzola, Rosario ^{[1
]}

di Monale e Bastia, Michela Buglione ^{[3
]}

Fersino, Sergio ^{[1
]}

Baiguini, Anna ^{[3
]}

Jereczek-Fossa, Barbara Alicja ^{[4
]}

Magrini, Stefano Maria ^{[3
]}

机构：

[1] Sacro Cuore Don Calabria Canc Care Ctr, Radiat Oncol, Negrar Verona, Italy

[2] San Camillo & Forlanini Hosp, Radiat Oncol, Rome, Italy

[3] Spedali Civili Brescia, Radiat Oncol, Brescia, Italy

[4] Univ Milan, European Inst Oncol, Radiat Oncol, Milan, Italy

[5] Univ Brescia, Brescia, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2017年 / 117卷

关键词：

Stereotactic radiotherapy; SABR; Renal cell carcinoma; Oligometastases; INITIAL CLINICAL-EXPERIENCE; DOSE-PER-FRACTION; BODY RADIOTHERAPY; SPINAL METASTASES; FOLLOW-UP; RADIOSURGERY; CANCER; IMMUNOTHERAPY; NEPHRECTOMY; KIDNEY;

D O I：

10.1016/j.critrevonc.2017.07.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Renal Cell Carcinoma (RCC) has historically been considered a radioresistant cancer, and radiotherapy was usually delivered with a palliative goal. Stereotactic ablative radiotherapy (SABR) allows the delivery of high doses on small treatment volumes in a safe and effective way, thus opening the doors to new applicationsof radiotherapy both in the treatment of the primary and oligometastasic disease. Aim of the current review is to explore the state of art of SABR in the therapeutic approach to RCC. (C) 2017 Elsevier B.V. All rights reserved.

引用

页码：48 / 56

页数：9

共 50 条

[41] Approaches to Oligometastatic Renal Cell Carcinoma
Nicolas Magne
Nicolas Milhade
Paul Sargos
Wafa Bouleftour
Current Oncology Reports, 2023, 25 : 251 - 256
[42] Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma
Raj, Rohit K.
Upadhyay, Rituraj
Wang, Shang-Jui
Singer, Eric A.
Dason, Shawn
CURRENT ONCOLOGY, 2023, 30 (12) : 10283 - 10298
[43] Approaches to Oligometastatic Renal Cell Carcinoma
Magne, Nicolas
Milhade, Nicolas
Sargos, Paul
Bouleftour, Wafa
CURRENT ONCOLOGY REPORTS, 2023, 25 (04) : 251 - 256
[44] Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma
Kroeze, Stephanie G. C.
Fritz, Corinna
Schaule, Jana
Siva, Shankar
Kahl, Klaus H.
Sundahl, Nora
Blanck, Oliver
Kaul, David
Adebahr, Sonja
Verhoeff, Joost J. C.
Skazikis, Georgios
Roeder, Falk
Geier, Michael
Eckert, Franziska
Guckenberger, Matthias
BJU INTERNATIONAL, 2021, 127 (06) : 703 - 711
[45] Stereotactic Ablative Radiotherapy for Oligometastatic Disease: a Treatment in Search of Evidence - a Response
Hargreaves, S.
Comins, C.
CLINICAL ONCOLOGY, 2016, 28 (08) : 503 - 504
[46] Advancing the Paradigm: Oligometastatic Disease and the Impact of Stereotactic Ablative Body Radiotherapy
Shor, D.
Khoo, V.
Jayaprakash, K. T.
CLINICAL ONCOLOGY, 2024, 36 (07) : 402 - 405
[47] Utilization of stereotactic ablative radiotherapy in the management of oligometastatic disease
Broomfield, J. A.
Greenspoon, J. N.
Swaminath, A.
CURRENT ONCOLOGY, 2014, 21 (03) : 115 - 117
[48] Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach
Ricardi, Umberto
Badellino, Serena
Filippi, Andrea Riccardo
JOURNAL OF RADIATION RESEARCH, 2016, 57 : I58 - I68
[49] Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma
Khriguian, Julia
Patrocinio, Horacio
Andonian, Sero
Aprikian, Armen
Kassouf, Wassim
Tanguay, Simon
Cury, Fabio L.
PRACTICAL RADIATION ONCOLOGY, 2022, 12 (01) : E34 - E39
[50] Stereotactic Ablative Radiotherapy for Oligometastatic Disease: Great Enthusiasm but Scant Evidence
Macbeth, F.
Treasure, T.
CLINICAL ONCOLOGY, 2022, 34 (05) : 313 - 317

← 1 2 3 4 5 →